Tiziana Life Sciences #TILS – Proposed US Public Offering August 6, 2019 – Posted in: Tiziana Life Sciences (TILS)

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Tiziana Announces Publication of Registration Statement on Form F-1 and Proposed U.S. Public Offering of ADSs New York and London, August 6, 2019 – Tiziana Life Sciences…

Tiziana Life Sciences (TILS) Tiziana Reports Phase 2a Clinical Data with Milciclib Monotherapy in patients with advanced Hepatocellular Carcinoma liver cancer July 21, 2019 – Posted in: Tiziana Life Sciences (TILS)

Milciclib was well tolerated and no drug related deaths were reported 28 out 31 treated patients were evaluable, with 14 patients completing the 6-month study duration 9 patients continued treatment under compassionate use, of which 5 are currently continuing with treatment New York/London, 22 July 2019 – Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced…

Tiziana Life Sciences #TILS – Proposed US Public Offering August 6, 2019 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences (TILS) Tiziana Reports Phase 2a Clinical Data with Milciclib Monotherapy in patients with advanced Hepatocellular Carcinoma liver cancer July 21, 2019 – Posted in: Tiziana Life Sciences (TILS)

Address

Contact

Social

LEGAL